VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 1,700 shares, an increase of 112.5% from the December 15th total of 800 shares. Based on an average trading volume of 9,000 shares, the short-interest ratio is presently 0.2 days.
Hedge Funds Weigh In On VanEck Biotech ETF
A number of hedge funds have recently added to or reduced their stakes in BBH. Wilmington Savings Fund Society FSB bought a new stake in VanEck Biotech ETF in the third quarter worth approximately $166,000. Jane Street Group LLC lifted its stake in shares of VanEck Biotech ETF by 401.7% in the 3rd quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock valued at $1,481,000 after purchasing an additional 6,684 shares during the last quarter. Kovitz Investment Group Partners LLC boosted its holdings in VanEck Biotech ETF by 4.6% in the third quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock worth $565,000 after purchasing an additional 141 shares in the last quarter. FSA Wealth Management LLC acquired a new position in VanEck Biotech ETF during the third quarter worth $54,000. Finally, Truvestments Capital LLC bought a new position in VanEck Biotech ETF during the third quarter valued at about $44,000. Institutional investors and hedge funds own 32.05% of the company’s stock.
VanEck Biotech ETF Price Performance
BBH traded down $1.02 during trading on Thursday, reaching $158.45. 10,570 shares of the stock traded hands, compared to its average volume of 10,927. The stock’s 50-day simple moving average is $162.70 and its two-hundred day simple moving average is $171.65. VanEck Biotech ETF has a fifty-two week low of $151.35 and a fifty-two week high of $183.64.
VanEck Biotech ETF Announces Dividend
About VanEck Biotech ETF
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Featured Stories
- Five stocks we like better than VanEck Biotech ETF
- 3 Tickers Leading a Meme Stock Revival
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- How to Short a Stock in 5 Easy StepsĀ
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.